Physician profile
Mark A Sargent
NPI 1013993377
$3,675.94
in general payments reported to CMS, 2019-2025
26 companies · $871 in 2025
The $871 reported for 2025 was more than what 82% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $150 · 2021: $606 · 2022: $638 · 2023: $400 · 2024: $256 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Gift: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.94 |
| Gift | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $832.77 | 2019-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $726.33 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $652.36 | 2021-2025 | |
| Novo Nordisk INC | $437.43 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $254.04 | 2019 | |
| Pfizer INC. | $86.67 | 2019-2023 | |
| Astellas Pharma US INC | $85.29 | 2023-2025 | Veozah |
| Agile Therapeutics, INC. | $62.24 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $56.34 | 2023 | |
| Organon LLC | $54.51 | 2021-2025 | Nexplanon |
| Allergan, INC. | $53.19 | 2019-2020 | |
| Daiichi Sankyo INC. | $46.02 | 2019 | |
| Exeltis, USA INC. | $45.93 | 2022-2023 | Slynd |
| Avion Pharmaceuticals | $41.05 | 2021-2022 | |
| Duchesnay USA Incorporated | $33.56 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $26.47 | 2025 | |
| Shield Therapeutics INC | $24.68 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.41 | 2022 | |
| Radius Health, INC. | $23.54 | 2024 | Tymlos |
| Therapeuticsmd, INC. | $20.90 | 2022 | |
| Millicent US INC | $20.44 | 2024 | Intrarosa |
| Medtronic, INC. | $19.61 | 2024 | Truclear |
| Evofem Biosciences, INC. | $18.47 | 2022 | |
| Olympus America INC. | $17.40 | 2019 | |
| Meditrina | $12.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.